Comparable Clinical Activity for Low-, High-Dose Clofarabine

This article originally appeared here.
Share this content:
Comparable Clinical Activity for Low-, High-Dose Clofarabine
Comparable Clinical Activity for Low-, High-Dose Clofarabine

(HealthDay News) -- Low and high doses of clofarabine have comparable clinical activity for the treatment of patients with higher-risk myelodysplastic syndrome (MDS), according to a study published in the February 1 issue of Cancer.

Stefan Faderl, MD, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues conducted a randomized study to evaluate the activity and safety of two doses (15 versus 30mg/m² daily for five days) of intravenous clofarabine in patients with higher-risk MDS. A cohort of 58 participants (median age, 68 years), including 15 patients (28%) with secondary MDS and 35 patients (60%) who had previously received DNA methyltransferase (DNMT) inhibitors, were adaptively randomized between the two dose groups.

The researchers found that the overall response rate (ORR) was 36%, including 26% of patients with complete remission (CR). The ORR was 41% at 15mg/m² and 29% at 30mg/m². Patients who had failed DNMT inhibitors had lower response rates (ORR, 17%; CR rate, 14%). The eight-week mortality rate was 19%, with a median survival of 7.4, 13.4, and 21.7 months for all patients, responders, and complete responders, respectively. For patients randomized to 30mg/m² of clofarabine, some of the adverse events, including hepatic and renal, were more severe (grade >2). Frequent complications included myelosuppression and infectious complications.

"Both the lower and higher doses of clofarabine have comparable clinical activity, but the lower dose appeared less toxic," the authors write.

Several authors disclosed financial ties to Genzyme, which manufactures clofarabine.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs